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Abstract
Background—The COMBINE (Combined Pharmacotherapies and Behavioral Intervention)
clinical trial recently evaluated the efficacy of pharmacotherapies, behavioral therapies, and their
combinations for the treatment of alcohol dependence. Previously, the cost and cost-effectiveness
of COMBINE have been studied. Policy makers, patients, and nonalcohol-dependent individuals
may be concerned not only with alcohol treatment costs but also with the impact of alcohol
interventions on broader social costs and outcomes.
Objectives—To estimate the sum of treatment costs plus the costs of health care utilization,
arrests, and motor vehicle accidents for the 9 treatments in COMBINE 3 years post-
randomization.
Research Design—A cost study based on a randomized controlled clinical trial.
Subjects—786 participants 3 years post-randomization.
Results—Multivariate results show no significant differences in mean costs between any of the
treatment arms as compared to medical management (MM) + placebo for the 3-year post-
randomization sample. The median costs of MM + acamprosate, MM + naltrexone, MM +
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acamprosate + naltrexone, and MM + acamprosate + combined behavioral intervention were
significantly lower than the median cost for MM + placebo.
Conclusions—The results show that social cost savings are generated relative to MM + placebo
by 3 years post-randomization, and the magnitude of these cost savings is greater than the costs of
the COMBINE treatment received 3 years prior. Our study suggests that several alcohol treatments
may indeed lead to reduced median social costs associated with health care, arrests, and motor
vehicle accidents.
Keywords
alcohol treatment; social costs; cost offsets
INTRODUCTION
Alcohol abuse and dependence impose significant costs to society, estimated at $184 billion
in 1998,1 and alcohol use is the third leading preventable cause of death.2 Altogether, 8.5%
of adults in the United States meet clinical criteria for alcohol abuse (4.7% or 9.7 million
adults) or alcohol dependence (3.8% or 7.9 million adults).3 The impact of alcohol use,
abuse, and dependence on society has led researchers to seek out treatments that reduce the
negative consequences of alcohol use disorders.
COMBINE was a multicenter, randomized controlled clinical trial (RCT) of alcohol
treatments sponsored by the National Institute on Alcohol Abuse and Alcoholism. The study
examined whether combinations of pharmacotherapies (acamprosate and naltrexone) and
behavioral therapies (medical management [MM] and combined behavioral intervention
[CBI]) treated alcohol dependence better than monotherapies. COMBINE participants at 11
sites were randomized into 9 treatment groups. Eight of the treatment groups (all receiving
MM) form a 2×2×2 factorial design in which patients were randomized to receive
acamprosate (active or placebo form), naltrexone (active or placebo form), and either CBI or
no additional behavioral therapy. The ninth treatment group received only CBI (no
medication, placebo, or MM).4
A separate study was funded to estimate the costs and cost-effectiveness of COMBINE in 9
of the 11 treatment sites.5,6 Zarkin and colleagues6 estimated the treatment costs and cost-
effectiveness of COMBINE at the end of 16 weeks of treatment from the treatment
provider’s perspective. Dunlap et al.7 added patient time costs to the treatment costs and re-
evaluated the costs and cost-effectiveness of COMBINE from the patient’s perspective.
In this paper, we expand the perspective of the analysis to include broader social outcomes
and costs over three years. Policy makers, patients, and nonalcohol-dependent individuals
may be concerned not only with alcohol treatment costs but also with the impact of alcohol
interventions on social costs, such as the costs of health care utilization, crime, and motor
vehicle accidents. An initially costly treatment intervention may incur smaller future social
costs, making the sum of treatment and social costs similar to or even less than other
treatment choices.
Despite the enormous social costs imposed by alcohol abuse, only a few studies have
examined the impact of alcohol treatment on these broader social costs in the context of
RCTs. Holder et al.8 examined the cost of medical care following 3 behavioral treatments as
part of the Project MATCH RCT. They found that total medical care declined post-treatment
for all 3 modalities, but there were no significant differences across the treatment modalities.
More recently, the UKATT Research Team9 evaluated the cost and cost-effectiveness of 2
behavioral treatments in an RCT. Both therapies showed similar and substantial savings of
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approximately 5 times the cost of treatment in terms of reduced expenditures for health care,
social services, and criminal justice services. This paper takes advantage of COMBINE’s
RCT design and the large number of behavioral and pharmacological treatment therapies
studied in COMBINE.
METHODS
Zarkin and colleagues designed a cost and cost-effectiveness study of COMBINE.5,6 The
social costs analyzed here are the sum of treatment costs and the economic costs of health
care utilization, arrests, and motor vehicle accidents. The costs of treatment are the same as
those estimated in Zarkin et al.6 and include pharmaceutical, labor, and laboratory and
nonlaboratory assessment costs for delivering the 9 COMBINE treatments through 16
weeks.
Broader social costs were measured using the following economic outcomes recorded on the
Economic Form-90:10 health care utilization, arrests, and motor vehicle accidents. Health
care utilization includes nights spent in a hospital and whether these were mental health or
substance abuse (MH/SA) related, nights in another MH/SA treatment facility, emergency
room (ER) visits, and other health care visits and whether these were MH/SA related.
Arrests are categorized as driving under the influence, other traffic violations, disorderly
conduct or public drunkenness, assault, motor vehicle theft, burglary, robbery, or other
arrests.
We recognize that intensity of care may vary in inpatient, outpatient, or ER settings.
Furthermore, variability exists in the extent of injuries incurred as a result of crimes or
motor vehicle accidents. Because we did not collect detailed information on the complexity
or the actual costs of these outcomes, we multiplied the economic outcomes by a
corresponding average unit cost, which was derived from the literature and updated to 2007
dollars with the medical services consumer price index. Unit costs for health care utilization
were mostly derived from French and Martin;11 the exception is the cost for a night in a
nonhospital MH/SA treatment facility, which was derived from Roebuck et al.12 We used
Miller et al.13 for costs per arrest by crime type. To be conservative, we used the “monetary
subtotal costs” for the unit costs for assault, robbery, motor vehicle theft, and burglary.
Monetary costs include policing costs, property damage/loss, health care costs, lost future
earnings, and adjudication and sanctioning costs. For the arrest categories not specifically
covered by Miller et al.—driving under the influence, other traffic violations, disorderly
conduct and public drunkenness, and other arrests—we used the “adjudication and
sanctioning” unit cost because health care costs, property damage, and earnings losses
typically would not be incurred in these cases. Finally, costs of motor vehicle accidents were
from Blincoe et al.14 To estimate the unit cost of an accident, we used the economic costs of
accidents excluding medical costs. For COMBINE participants, health care utilization
associated with accidents is captured in the Form-90 health care utilization measures. Our
accident unit cost, which is sizeable, represents a conservative estimate because it does not
include accident-related medical costs for those involved in reported accidents who are not
patients in the COMBINE trial.
The COMBINE treatment and social costs were summed through 3 years post-
randomization. This 3-year sample includes only the 9 sites that were part of the cost-
effectiveness follow-up study and patients with at least 1 follow-up record of the Economic
Form-90 both before and after the main trial stopped following patients (1 year after
treatment). Of 1,144 participants who were randomized in the main trail from the 9 sites,
1053 participants (92% of those randomized) had a Form-90 after week 16 when treatment
ended, and 786 participants (75% of those completing treatment) were included in the 3-year
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economic study. No differential attrition existed across the treatment arms from either the
randomized group or the week 16 sample.
In the 3-year sample, 71% of patients have complete records for the 11 interview dates. To
mitigate attrition bias, we included individuals with complete and incomplete data.
Individuals with missing interview dates have lower cumulative costs, all else equal. To
account for these cost differences, we included a covariate in our regression analyses for the
total number of reporting days represented by the costs.
Because of the skewness of the data, the mean, median, and 90th percentile of costs were
estimated for 3-year post-randomization sample. Ordinary least squares (OLS) and median
regression models were estimated with covariates for treatment intervention, treatment sites,
days of cost reporting (measured as the deviation from the number of days in the entire
follow-up period), and baseline costs (measured as the deviation from the baseline mean).
We focused on individual coefficient estimates that compare the mean or median cost of
each treatment arm to the mean or median cost of the reference category, MM + placebo; t-
tests of individual coefficient estimates indicate whether the treatment has significantly
different total costs compared to MM + placebo. In addition, we performed F-tests of the
hypotheses that the treatment coefficients are jointly equal to each other and that the
treatment coefficients are jointly equal to zero, which is equivalent to testing whether the
treatment coefficients as a group are jointly equal to the coefficient on MM + placebo.
When reporting multivariate regression results, we note coefficients that are significantly
different from zero at the 1% and 5% levels. We also included p-values of the coefficient
estimates so that readers who have a concern about the number of treatment intervention
comparisons (9) may use a more stringent significance level.
RESULTS
Unit cost estimates used in the study are presented in Table 1. As shown, motor vehicle
accidents are the most expensive economic outcome, due in large part to the cost of motor
vehicle repair, and any arrest is more expensive than a day or night of health care utilization.
The most expensive arrest is robbery, followed by motor vehicle theft and assault.
Because the unit cost for each outcome is the same across the treatment arms, cost
differences across arms reflect differences in the number of events that occur. As shown in
Table 2, the mean cost across all treatment arms 3 years post-randomization was $13,965;
the median cost was $5,861; and the 90th percentile was $34,391. Health care costs
represented 52% of total costs, and motor vehicle accident costs represented 33% of total
costs. Arrest costs accounted for less than 10% of total costs (7.9%), and COMBINE
treatment costs represented less than 10% of total costs (6.3%). MM + acamprosate +
naltrexone had the lowest mean cost ($11,742), and MM + acamprosate + CBI had the
lowest median cost ($4,639). CBI only had the largest mean cost ($14,938), and MM +
placebo had the largest median cost ($8,637). Health care, arrest, and motor vehicle accident
costs were skewed as shown by the mean exceeding the median and by the large values for
the 90th percentile. This skewness arose because expensive events such as inpatient care,
arrests, and auto accidents occurred rarely, but when they did, they added substantially to
costs. For example, for several treatments, the 90th percentile of motor vehicle costs was
$14,576, the cost of 1 auto accident, but the median number of accidents for all treatments is
zero.
COMBINE treatment costs do not appear to be positively related to total social costs and, in
fact, are suggestive of a negative relationship. For example, MM + placebo had the lowest
mean ($406) and median ($410) treatment costs and yet had the third largest mean total
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costs ($14,865) and the largest median total costs ($8,637); MM + acamprosate + naltrexone
+ CBI had the largest mean ($1,379) and median ($1,492) treatment costs but only the fifth
largest mean total costs and the second largest median total costs.
The OLS results in Table 3 show that point estimates were negative, which indicated that the
interventions had lower mean treatment + social costs (but not significantly so) 3 years post-
randomization compared with MM + placebo. We cannot reject the null hypothesis that the
coefficients on the treatment arms were jointly equal to each other (F(7,767) = 0.28, P = .
96), nor can we reject the null hypothesis that the coefficients on the treatment arms were
jointly equal to zero (F(8,767) = 0.36, P = .94), implying that there were no significant
differences in mean costs between the treatment arms as a group compared with MM +
placebo for the 3-year post-randomization sample.
The median regressions in Table 3 show several treatment interventions that had statistically
significant (at the .05 level or lower) median cost differences relative to MM + placebo. At 3
years post-randomization, the median costs of MM + acamprosate, MM + naltrexone, MM +
acamprosate + naltrexone, and MM + acamprosate + CBI were significantly lower than the
median cost for MM + placebo (P < .05). These median cost differences ranged from $2,500
to $3,800 lower than the median costs of MM + placebo. The F-test on the median model
shows that we fail to reject the null hypothesis that the treatment coefficients were jointly
equal to each other (F(7,767) = 1.34, P = 0.23). An F-test also shows that we reject the
hypothesis that the coefficients were jointly equal to zero at the .10 level but not at the .05
level (F(8,767) = 1.85, P = 0.07). This latter F-test provides some evidence, although not
definitive, that the treatment interventions as a group reduced median 3-year costs relative to
MM + placebo.
The coefficients on days of cost reporting and baseline costs for the OLS and median
regressions were significant (P < .01 for all but the days coefficient in the OLS model) and
have the expected signs: individuals with interviews covering more reporting days had
greater mean and median costs post-randomization, and individuals with greater baseline
costs had greater mean and median costs post-randomization.
DISCUSSION
We estimated the sum of the COMBINE treatment costs plus the social costs of health care
use, arrests, and motor vehicle accidents over three years for the 9 alcohol dependence
treatments in the COMBINE study.4 If alcohol treatment interventions generate future social
cost savings, then these treatment interventions are more attractive from the social
perspective because they generate social benefits that are not limited to alcohol-dependent
patients. Furthermore, adding social costs to treatment costs may change the relative
attractiveness of costly interventions—an initially costly treatment intervention may result in
lower future social costs, increasing its attractiveness relative to other alternatives.
Our multivariate results show no significant differences in mean costs between any of the
treatment arms as compared to MM + placebo for the 3-year post-randomization sample. We
hypothesize that this lack of statistical significance was largely caused by the skewness of
the data, which in turn was caused by the occurrence of rare but expensive inpatient hospital
stays, arrests, and motor vehicle accidents. These high cost outliers increased both the mean
and variance of costs and typically a larger sample size is required to show significant cost
differences between treatment interventions.
Because our sample size was predetermined by the design of COMBINE and could not be
increased, we addressed the skewness by estimating median regression models. In contrast
to mean costs, the medians are less affected by high cost outliers. At 3 years post-
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randomization, the median costs of MM + acamprosate, MM + naltrexone, MM +
acamprosate + naltrexone, and MM + acamprosate + CBI were significantly lower than the
median cost for MM + placebo. Median cost differences ranged from $2,500 to $3,800 less
than the median costs of MM + placebo. These results show that social cost savings are
generated relative to MM + placebo by 3 years post-randomization and, importantly, the
magnitude of these cost savings is greater than the costs of the COMBINE treatment
received 3 years prior. Qualitatively, this result is similar to the UKATT9 results, although it
is difficult to make a definitive comparison because UKATT did not have a placebo
condition, as was the case here.
To explore our results in more detail, we re-ran our mean and median regression analyses
with just the initial treatment costs plus health care expenses (i.e., excluding arrests and
motor vehicle accidents). We found that the 3-year post-randomization median results were
very different from Table 3: no treatment intervention was individually significant, only 4 of
the coefficients were negative in sign, and we could not reject the null that the coefficients
were jointly equal to zero (P = .37). Thus, we concluded that there are no offsetting health
care costs 3 years post-randomization and that including arrests and motor vehicle accident
outcomes had a substantial effect on our estimated social cost differences.
As an alternative to our OLS specification, we transformed our model to account for the
skewness of our cost data. We followed the methodology described by Manning and
Mullahy15 to determine the appropriate data transformation. This process suggested a
generalized linear model with a log-link and gamma distribution. With this model, the
differences in costs represented by the treatment arm coefficients and the costs of MM +
placebo were the same in sign (with one exception) and generally of a similar magnitude as
the differences in means shown in Table 3 for the OLS models. These results highlight the
robustness of the OLS model to our skewed data distribution, and we report the OLS
specification along with the median regression model.
A related literature examines the potential cost-offset of alcohol treatment by evaluating
whether alcohol treatment as compared to no treatment reduces subsequent medical
utilization and health care costs (e.g., 16–21). The results of this literature vary widely due
in part to differences in study population, study design, and comparison group. For example,
Parthasarathty et al.18 found that inpatient, ER, and total medical costs declined 18 months
after intake into the outpatient chemical dependency program at Sacramento Kaiser
Permanente; non-ER outpatient costs were unchanged. Booth et al.19 found differences in
the use of inpatient and outpatient care as alcohol treatment varied in intensity from short
detox to extended detox to incomplete treatment and completed treatment. In their study of
male alcoholics in the VA, Booth et al. found that inpatient days and outpatient visits
increased post-alcohol treatment for all treatment groups; however, inpatient medical care
decreased and substance abuse inpatient care increased for most treatment groups; overall,
the use of inpatient services increased for these groups. In a study of adults receiving
benefits from a behavioral managed care company and its parent medical care insurance
company, Kane et al.16 found that the pattern of outpatient and inpatient medical utilization
before and after alcoholism treatment was symmetric: utilization increased gradually in the
year before treatment and then decreased post-treatment. Their results suggested that
alcoholism treatment did not reduce subsequent health care utilization.
In contrast to previous cost offset papers of which we are aware, our paper takes advantage
of the COMBINE trial’s RCT design. Related papers typically create an untreated alcohol-
dependent group from health care records. Weaknesses of this design include the potential
regression to a lower mean utilization post-treatment and potential selection bias caused by
the inability to control for unobserved differences between alcohol-dependent patients who
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do and do not go to alcohol treatment. Our RCT design does not have these weaknesses and
thus our conclusions have more internal validity.
Our paper has several limitations. First, our analysis examines only a subset of possible
social costs: health care utilization, arrests, and motor vehicle accidents. We did not examine
labor market outcomes because of the difficulty of placing a dollar value on all the
outcomes, such as the value of being “unemployed.” But because a majority of the
COMBINE patients were not unemployed (approximately 75% were employed at intake and
at weeks 52 and 156), excluding this variable is unlikely to change our conclusions. Second,
although we drew on peer-reviewed literature for our unit cost estimates, we exercised some
judgment in selecting the unit cost components to include. For example, in selecting the unit
costs of arrests, we used the monetary subtotal of arrest costs, but we adopted a conservative
approach and did not include accident-related medical costs for those involved in accidents
who were not patients in the COMBINE trial or nonmonetary cost estimates of pain and
suffering, which would have increased our unit cost estimates substantially. Although the
size of the cost differences would increase with larger unit cost estimates, there is no reason
to believe that our conservative approach affects our comparisons across the alternative
treatment interventions because the unit costs were applied consistently to all treatment
arms. Third, all treatment interventions are compared to MM + placebo, which is not a “no
treatment” group as MM plays an important treatment role. If the comparison group did not
include MM, an active treatment, the estimated cost differences may have been even larger
than estimated here. Fourth, we recognize that expensive rare events such as lengthy hospital
stays, arrests, and motor vehicle accidents may greatly affect mean costs especially given the
size of our sample. Our analysis of median costs, which are less affected by outliers, is one
way to address this concern. In the future, additional RCT studies with larger sample sizes
are needed to confirm the joint and individual impact of alcohol treatment on mean and
median costs.
Finally, while it is reasonable to compare the clinical outcomes with the cost results reported
here, we are reluctant to make causal statements about the relationship between specific
clinical therapies and the impact on costs 3 years post-randomization because COMBINE
was not designed for that analysis. We do note, however, that MM + acamprosate +
naltrexone had the highest mean effectiveness6 for all 3 clinical outcomes (percent days
absent, proportion of patients who avoid heavy drinking, and proportion of patients with
good clinical outcomes) and also the largest estimated decrease in median costs 3 years post-
randomization. Similarly, MM + acamprosate + CBI and MM + naltrexone had the next
largest estimated median cost reductions and the second or third largest mean effectiveness
estimates across the clinical outcomes. Additional analyses with larger clinical and
economic samples and/or analyses that develop structural relationships between clinical
outcomes and cost would be required to be more definitive about the relationship. In the
meantime, our study suggests that several alcohol treatments—MM + acamprosate, MM +
naltrexone, MM + acamprosate + naltrexone, and MM + acamprosate + CBI—may indeed
lead to reduced median social costs associated with health care, arrests, and motor vehicle
accidents.
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Table 1
Unit Costs
Variable Unit Cost (2007 $) Source
Health care utilization
 Hospital night 1,592 French and Martin (1996)11
  Mental health/substance abuse (MH/SA) 1,481 French and Martin (1996)11
 Nights in other MH/SA treatment facility 132 Roebuck et al. (2003)12
 Emergency department visit 793 French and Martin (1996)11
 Other health care (outpatient/counseling) 142 French and Martin (1996)11
  MH/SA 93 French and Martin (1996)11
Arrests
 Driving under the influence 2,971 Miller et al. (2006)13
 Other traffic 2,971 Miller et al. (2006)13
 Public drunkenness 2,971 Miller et al. (2006)13
 Assault 8,261 Miller et al. (2006)13
 Motor vehicle theft 8,874 Miller et al. (2006)13
 Burglary 4,587 Miller et al. (2006)13
 Robbery 12,171 Miller et al. (2006)13
 Not specified in list above 2,971 Miller et al. (2006)13
Motor vehicle accidents 14,576 Blincoe et al. (2002)14














































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Variables OLS (1) Median Regression (2)
Constant 14,049.07 10,204.39
(2,843.98)** (1,325.35)**
p < 0.01 p < 0.01
MM + acamprosate −1,979.77 −2,547.31
(2,792.78) (1,290.97)*
p = 0.48 p = 0.05
MM + naltrexone −763.18 −2,991.12
(2,863.35) (1,329.52)*
p = 0.79 p = 0.03
MM + acamprosate + naltrexone −3,739.66 −3,871.26
(2,837.07) (1,321.55)**
p = 0.19 p < 0.01
MM + placebo + CBI −764.05 −1,897.29
(2,847.06) (1,326.87)
p = 0.79 p = 0.15
MM + acamprosate + CBI −3,062.88 −3,276.55
(2,791.10) (1,293.45)*
p = 0.27 p = 0.01
MM + naltrexone + CBI −2,522.16 −1,176.21
(2,839.71) (1,319.85)
p = 0.38 p = 0.37
MM + acamprosate + naltrexone + CBI −1,863.15 −734.56
(2,834.27) (1,320.53)
p = 0.51 p = 0.58
CBI only −1,230.32 −1,690.61
(2,843.80) (1,317.97)
p = 0.67 p = 0.20
Days 12.78 9.37
(4.96)* (2.28)**
p = 0.01 p < 0.01
Baseline costs 0.44 0.49
(0.12)** (0.05)**
p < 0.01 p < 0.01
Notes: MM = medical management; CBI = combined behavioral intervention.
Standard errors in parentheses.
*
Significant at 5%;
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**
Significant at 1%.
Coefficients on treatment arms compare to MM + placebo.
Number of observations is 786 for 3-year sample.
Regressions controlled for difference in costs between the 9 sites in the 3-year sample.
Med Care. Author manuscript; available in PMC 2011 July 5.
